Biohaven Pharma (BHVN) and Pfizer (PFE) announce strategic collaboration for the global commercialization of NURTEC ODT outside the United States
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Biohaven (BHVN) Defended at William Blair
November 9, 2021 11:58 AM ESTWilliam Blair analyst Tim Lugo is out defending Biohaven Pharmaceutical Holding (NYSE: BHVN) on weakness after the company agreed to a strategic deal with Pfizer (NYSE: PFE) versus an outright takeover.
The analyst commented, "We view Nurtec ODT as the... More
Biohaven Pharma (BHVN) Announces Strategic Collaboration with Pfizer (PFE) for Commercialization of Rimegepant Outside the US
November 9, 2021 7:48 AM EST(Updated - November 9, 2021 7:51 AM EST)
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec® ODT in the U.S., and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults. An application for the approval of rimegepant is currently under review by the European Medicines Agency and several additional regulatory... More
Biohaven Pharma (BHVN) Halted, News Pending
November 9, 2021 7:24 AM ESTBiohaven Pharma (NYSE: BHVN) Halted, News Pending
